So the studies in progress is relatively small Phase 2 study that focuses on patients with lymphoma and advanced lymphoma especially diffused B-cell, large B-cell lymphomas and as we mentioned, we've already seen two very significant durable partial responses out of two people who were treated.
These were really remarkable responses that have impressed not just us but the investigators and the folks at AstraZeneca and other companies who were interested in this drug.
And so, the goal is to give this drug a chance to demonstrate in larger numbers of these patients that it really is as active as it appears to be. And the milestone is graduated depending on the number of responses we see in a very small in what constitutes a very small number of patients really.
So we think there is a very good probability that the drug will display very good activity here and that we will see this whole milestone and the study we believe could be completed we will get to the end point here pretty quickly.